Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach

Vikas Jha; Ajit Kumar; Geetika Preman; Kunal Gharat; Muskaan Mulani; Shalmali Pendse; Kabir Thakur; Anjali Bhosale; Siddhartha Pandya; Arpita Marick

doi:doi:10.11648/j.bsi.20220702.13

Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach

Vikas Jha, Ajit Kumar, Geetika Preman, Kunal Gharat, Muskaan Mulani, Shalmali Pendse, Kabir Thakur, Anjali Bhosale, Siddhartha Pandya, Arpita Marick

Published in Biomedical Statistics and Informatics (Volume 7, Issue 2)

Received: 31 May 2022 Accepted: 20 June 2022 Published: 30 June 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

While tuberculosis is a curable disease, Mycobacterium tuberculosis (M. tb), its etiological agent, remains a major human pathogen. For thousands of years of human life, this pathogen leads to more human deaths than any other infectious agent. Relatively affordable new drugs for the treatment of this lethal disease need to be developed in light of global TB infections. The current study aims to screen a broad spectrum of bioactive compounds, along with standard anti-tubercular drugs against Topoisomerase II protein of Mtb. The Lipinski rule was employed for the initial screening of the phytochemicals based on their pharmacokinetic properties. The 75 shortlisted compounds were subjected to molecular docking analysis with the Topoisomerase II receptor, which revealed six molecules Glyceollin-I, Fumarine, Chelidonine, Alstonine, Tuberosin, and Asarinin, as potential inhibitors against the receptor. Furthermore, the toxicity profiles of these six compounds were evaluated, and Glyceollin-I, Alstonine, and Tuberosin were shown to be the safest as compared to the others. The MD simulation analyses of these compounds in complexation with the receptor confirmed that the receptor-Alstonine complex was the most stable. Thus, the findings of our study will contribute to a better understanding of the Mycobacterial Topoisomerase II protein target and pave the way for the development of a novel therapeutic candidate drug to treat this disease.

Published in	Biomedical Statistics and Informatics (Volume 7, Issue 2)
DOI	10.11648/j.bsi.20220702.13
Page(s)	31-40
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Bioactive Compounds, Molecular Docking, MD Simulations, Mycobacterium tuberculosis, Topoisomerase II Receptor

References

[1]	S. Kumar et al., “The phytochemical bergenin as an adjunct immunotherapy for tuberculosis in mice,” J. Biol. Chem., vol. 294, no. 21, pp. 8555–8563, 2019, doi: 10.1074/jbc.RA119.008005.
[2]	K. A. Abrahams et al., “Anti-tubercular derivatives of rhein require activation by the monoglyceride lipase Rv0183,” Cell Surf., vol. 6, no. April, 2020, doi: 10.1016/j.tcsw.2020.100040.
[3]	M. Mori et al., “An Overview on the Potential Antimycobacterial Agents Targeting Serine/Threonine Protein Kinases from Mycobacterium tuberculosis.,” Curr. Top. Med. Chem., vol. 19, no. 9, pp. 646–661, 2019, doi: 10.2174/1568026619666190227182701.
[4]	H. Tomioka, “Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.,” Current pharmaceutical design, vol. 20, no. 27. United Arab Emirates, pp. 4305–4306, 2014, doi: 10.2174/1381612819666131118203915.
[5]	M. A. Reiche, D. F. Warner, and V. Mizrahi, “Targeting DNA replication and repair for the development of novel therapeutics against tuberculosis,” Front. Mol. Biosci., vol. 4, no. NOV, pp. 1–18, 2017, doi: 10.3389/fmolb.2017.00075.
[6]	H. Rahimi, A. Najafi, H. Eslami, B. Negahdari, and M. M. Moghaddam, “Identification of novel bacterial DNA gyrase inhibitors: An in silico study,” Research in Pharmaceutical Sciences, vol. 11, no. 3. pp. 233–242, 2016.
[7]	M. S. Setzer, J. Sharifi-Rad, and W. N. Setzer, “The search for herbal antibiotics: An in-silico investigation of antibacterial phytochemicals,” Antibiotics, vol. 5, no. 3, 2016, doi: 10.3390/antibiotics5030030.
[8]	T. Khan, K. Sankhe, V. Suvarna, A. Sherje, K. Patel, and B. Dravyakar, “DNA gyrase inhibitors: Progress and synthesis of potent compounds as antibacterial agents,” Biomed. Pharmacother., vol. 103, no. March, pp. 923–938, 2018, doi: 10.1016/j.biopha.2018.04.021.
[9]	L. Li, X. Le, L. Wang, Q. Gu, H. Zhou, and J. Xu, “Discovering new DNA gyrase inhibitors using machine learning approaches,” RSC Adv., vol. 5, no. 128, pp. 105600–105608, 2015, doi: 10.1039/c5ra22568j.
[10]	V. Nagaraja, A. A. Godbole, S. R. Henderson, and A. Maxwell, “DNA topoisomerase I and DNA gyrase as targets for TB therapy,” Drug Discov. Today, vol. 22, no. 3, pp. 510–518, 2017, doi: 10.1016/j.drudis.2016.11.006.
[11]	J. K. Kumar, A. G. Devi Prasad, and V. Chaturvedi, “Phytochemical screening of five medicinal legumes and their evaluation for in vitro anti-tubercular activity.,” Ayu, vol. 35, no. 1, pp. 98–102, Jan. 2014, doi: 10.4103/0974-8520.141952.
[12]	H. M. Berman, K. Henrick, H. Nakamura (2003) Announcing the worldwide Protein Data Bank Nature Structural Biology 10 (12): 980.
[13]	“Dr. Duke’s Phytochemical and Ethnobotanical Databases.” https://phytochem.nal.usda.gov/phytochem/search.
[14]	Schrödinger LLC, “The PyMOL Molecular Graphics System, Version 2.4,” Schrödinger LLC. 2020.
[15]	A. Daina, O. Michielin, and V. Zoete, “SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules,” Sci. Rep., vol. 7, no. January, pp. 1–13, 2017, doi: 10.1038/srep42717.
[16]	G. M. Morris et al., “AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility.,” J. Comput. Chem., vol. 30, no. 16, pp. 2785–2791, Dec. 2009, doi: 10.1002/jcc.21256.
[17]	O. Trott and A. J. Olson, “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.,” J. Comput. Chem., vol. 31, no. 2, pp. 455–461, Jan. 2010, doi: 10.1002/jcc.21334.
[18]	M. N. Drwal, P. Banerjee, M. Dunkel, M. R. Wettig, and R. Preissner, “ProTox: A web server for the in silico prediction of rodent oral toxicity,” Nucleic Acids Res., vol. 42, no. W1, pp. 3–8, 2014, doi: 10.1093/nar/gku401.
[19]	Abraham, Mark James, Teemu Murtola, Roland Schulz, Szilárd Páll, Jeremy C Smith, Berk Hess, and Erik Lindahl. 2015. “GROMACS: High Performance Molecular Simulations through Multi-Level Parallelism from Laptops to Supercomputers.” SoftwareX 1–2: 19–25. https://doi.org/https://doi.org/10.1016/j.softx.2015.06.001.
[20]	Schüttelkopf, Alexander W, and Daan M F van Aalten. 2004. “PRODRG: A Tool for High-Throughput Crystallography of Protein-Ligand Complexes.” Acta Crystallographica. Section D, Biological Crystallography 60 (Pt 8): 1355–63. https://doi.org/10.1107/S0907444904011679.
[21]	C. A. Lipinski, “Lead- and drug-like compounds: The rule-of-five revolution,” Drug Discov. Today Technol., vol. 1, no. 4, pp. 337–341, 2004, doi: 10.1016/j.ddtec.2004.11.007.
[22]	L. G. Ferreira, R. N. Dos Santos, G. Oliva, and A. D. Andricopulo, Molecular docking and structure-based drug design strategies, vol. 20, no. 7. 2015.
[23]	S. A. SAEED, A. H. GILANI, R. U. MAJOO, and B. H. SHAH, “ANTI-THROMBOTIC AND ANTI-INFLAMMATORY ACTIVITIES OF PROTOPINE,” Pharmacol. Res., vol. 36, no. 1, pp. 1–7, 1997, doi: https://doi.org/10.1006/phrs.1997.0195.
[24]	E. Ernst and K. Schmidt, “Ukrain - a new cancer cure? A systematic review of randomised clinical trials.,” BMC Cancer, vol. 5, p. 69, Jul. 2005, doi: 10.1186/1471-2407-5-69.
[25]	Q. Lei, H. Liu, Y. Peng, and P. Xiao, “In silico target fishing and pharmacological profiling for the isoquinoline alkaloids of Macleaya cordata (Bo Luo Hui),” Chinese Med. (United Kingdom), vol. 10, no. 1, pp. 1–20, 2015, doi: 10.1186/s13020-015-0067-4.
[26]	Y. Su, S. Li, N. Li, L. Chen, J. Zhang, and J. Wang, “Seven alkaloids and their antibacterial activity from Hypecoum erectum L.,” J. Med. Plant Res., vol. 5, no. 22, pp. 5428–5432, 2011.
[27]	R. Herrmann, J. Roller, C. Polednik, and M. Schmidt, “Effect of chelidonine on growth, invasion, angiogenesis and gene expression in head and neck cancer cell lines,” Oncol. Lett., vol. 16, no. 3, pp. 3108–3116, 2018, doi: 10.3892/ol.2018.9031.
[28]	J. Lenfeld, M. Kroutil, E. Marsalek, J. Slavík, V. Preininger, and V. Simánek, “Antiinflammatory activity of quaternary benzophenanthridine alkaloids from Chelidonium majus,” Planta Med., vol. 43, no. 2, pp. 161–165, 1981, doi: 10.1055/s-2007-971493.
[29]	J. E. Park et al., “Alkaloids from Chelidonium majus and their inhibitory effects on LPS-induced NO production in RAW264.7 cells,” Bioorganic Med. Chem. Lett., vol. 21, no. 23, pp. 6960–6963, 2011, doi: 10.1016/j.bmcl.2011.09.128.
[30]	S. Zielińska et al., “The Activity of Isoquinoline Alkaloids and Extracts from Chelidonium majus against Pathogenic Bacteria and Candida sp.,” Toxins (Basel)., vol. 11, no. 7, Jul. 2019, doi: 10.3390/toxins11070406.
[31]	E. Elisabetsky and L. Costa-Campos, “The alkaloid alstonine: A review of its pharmacological properties,” Evidence-based Complement. Altern. Med., vol. 3, no. 1, pp. 39–48, 2006, doi: 10.1093/ecam/nek011.
[32]	M. Gandhi and V. K. Vinayak, “Preliminary evaluation of extracts of Alstonia scholaris bark for in vivo antimalarial activity in mice.,” J. Ethnopharmacol., vol. 29, no. 1, pp. 51–57, Apr. 1990, doi: 10.1016/0378-8741(90)90097-d.
[33]	L. Costa-Campos, D. R. Lara, D. S. Nunes, and E. Elisabetsky, “Antipsychotic-like profile of alstonine,” Pharmacol. Biochem. Behav., vol. 60, no. 1, pp. 133–141, 1998, doi: 10.1016/S0091-3057(97)00594-7.
[34]	B. S. Joshi and V. N. Kamat, “Tuberosin, a new pterocarpan from Pueraria tuberosa DC.,” J. Chem. Soc. Perkin 1, vol. 9, pp. 907–911, 1973, doi: 10.1039/p19730000907.
[35]	N. Pandey and Y. B. Tripathi, “Antioxidant activity of tuberosin isolated from Pueraria tuberose Linn,” J. Inflamm., vol. 7, pp. 1–8, 2010, doi: 10.1186/1476-9255-7-47.
[36]	Y. Ma, K. Xu, S. Wang, and Y. Han, “Simultaneous Determination of Two Epimeric Furofuran Lignans (Sesamin and Asarinin) of Asarum heterotropoides Extract in Rat Plasma by LC/MS/MS: Application to Pharmacokinetic Study,” J. Chromatogr. Sci., vol. 52, no. 8, pp. 793–798, 2013, doi: 10.1093/chromsci/bmt114.
[37]	R. O. Bussey et al., “Antimycobacterial furofuran lignans from the roots of anemopsis californica,” Planta Med., vol. 80, no. 6, pp. 498–501, 2014, doi: 10.1055/s-0034-1368352.
[38]	F. Peter Guengerich, “Mechanisms of drug toxicity and relevance to pharmaceutical development,” Drug Metab. Pharmacokinet., vol. 26, no. 1, pp. 3–14, 2011, doi: 10.2133/dmpk.DMPK-10-RV-062.
[39]	A. Vedani and M. Smiesko, “In silico toxicology in drug discovery - Concepts based on three-dimensional models,” ATLA Altern. to Lab. Anim., vol. 37, no. 5, pp. 477–496, 2009, doi: 10.1177/026119290903700506.
[40]	B. A. Lipsky and C. A. Baker, “Fluoroquinolone toxicity profiles: A review focusing on newer agents,” Clin. Infect. Dis., vol. 28, no. 2, pp. 352–364, 1999, doi: 10.1086/515104.
[41]	R. Stahlmann and H. Lode, “Toxicity of quinolones,” Drugs, vol. 58, no. SUPPL. 2, pp. 37–42, 1999, doi: 10.2165/00003495-199958991-00005.

Cite This Article

Plain Text BibTeX RIS

APA Style

Vikas Jha, Ajit Kumar, Geetika Preman, Kunal Gharat, Muskaan Mulani, et al. (2022). Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach. Biomedical Statistics and Informatics, 7(2), 31-40. https://doi.org/10.11648/j.bsi.20220702.13

Copy | Download

ACS Style

Vikas Jha; Ajit Kumar; Geetika Preman; Kunal Gharat; Muskaan Mulani, et al. Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach. Biomed. Stat. Inform. 2022, 7(2), 31-40. doi: 10.11648/j.bsi.20220702.13

Copy | Download

AMA Style

Vikas Jha, Ajit Kumar, Geetika Preman, Kunal Gharat, Muskaan Mulani, et al. Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach. Biomed Stat Inform. 2022;7(2):31-40. doi: 10.11648/j.bsi.20220702.13

Copy | Download

@article{10.11648/j.bsi.20220702.13,
  author = {Vikas Jha and Ajit Kumar and Geetika Preman and Kunal Gharat and Muskaan Mulani and Shalmali Pendse and Kabir Thakur and Anjali Bhosale and Siddhartha Pandya and Arpita Marick},
  title = {Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach},
  journal = {Biomedical Statistics and Informatics},
  volume = {7},
  number = {2},
  pages = {31-40},
  doi = {10.11648/j.bsi.20220702.13},
  url = {https://doi.org/10.11648/j.bsi.20220702.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bsi.20220702.13},
  abstract = {While tuberculosis is a curable disease, Mycobacterium tuberculosis (M. tb), its etiological agent, remains a major human pathogen. For thousands of years of human life, this pathogen leads to more human deaths than any other infectious agent. Relatively affordable new drugs for the treatment of this lethal disease need to be developed in light of global TB infections. The current study aims to screen a broad spectrum of bioactive compounds, along with standard anti-tubercular drugs against Topoisomerase II protein of Mtb. The Lipinski rule was employed for the initial screening of the phytochemicals based on their pharmacokinetic properties. The 75 shortlisted compounds were subjected to molecular docking analysis with the Topoisomerase II receptor, which revealed six molecules Glyceollin-I, Fumarine, Chelidonine, Alstonine, Tuberosin, and Asarinin, as potential inhibitors against the receptor. Furthermore, the toxicity profiles of these six compounds were evaluated, and Glyceollin-I, Alstonine, and Tuberosin were shown to be the safest as compared to the others. The MD simulation analyses of these compounds in complexation with the receptor confirmed that the receptor-Alstonine complex was the most stable. Thus, the findings of our study will contribute to a better understanding of the Mycobacterial Topoisomerase II protein target and pave the way for the development of a novel therapeutic candidate drug to treat this disease.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach
AU  - Vikas Jha
AU  - Ajit Kumar
AU  - Geetika Preman
AU  - Kunal Gharat
AU  - Muskaan Mulani
AU  - Shalmali Pendse
AU  - Kabir Thakur
AU  - Anjali Bhosale
AU  - Siddhartha Pandya
AU  - Arpita Marick
Y1  - 2022/06/30
PY  - 2022
N1  - https://doi.org/10.11648/j.bsi.20220702.13
DO  - 10.11648/j.bsi.20220702.13
T2  - Biomedical Statistics and Informatics
JF  - Biomedical Statistics and Informatics
JO  - Biomedical Statistics and Informatics
SP  - 31
EP  - 40
PB  - Science Publishing Group
SN  - 2578-8728
UR  - https://doi.org/10.11648/j.bsi.20220702.13
AB  - While tuberculosis is a curable disease, Mycobacterium tuberculosis (M. tb), its etiological agent, remains a major human pathogen. For thousands of years of human life, this pathogen leads to more human deaths than any other infectious agent. Relatively affordable new drugs for the treatment of this lethal disease need to be developed in light of global TB infections. The current study aims to screen a broad spectrum of bioactive compounds, along with standard anti-tubercular drugs against Topoisomerase II protein of Mtb. The Lipinski rule was employed for the initial screening of the phytochemicals based on their pharmacokinetic properties. The 75 shortlisted compounds were subjected to molecular docking analysis with the Topoisomerase II receptor, which revealed six molecules Glyceollin-I, Fumarine, Chelidonine, Alstonine, Tuberosin, and Asarinin, as potential inhibitors against the receptor. Furthermore, the toxicity profiles of these six compounds were evaluated, and Glyceollin-I, Alstonine, and Tuberosin were shown to be the safest as compared to the others. The MD simulation analyses of these compounds in complexation with the receptor confirmed that the receptor-Alstonine complex was the most stable. Thus, the findings of our study will contribute to a better understanding of the Mycobacterial Topoisomerase II protein target and pave the way for the development of a novel therapeutic candidate drug to treat this disease.
VL  - 7
IS  - 2
ER  -

Copy | Download

Author Information

Vikas Jha

National Facility for Biopharmaceuticals, Guru Nanak Khalsa College, Mumbai, India
Ajit Kumar

National Facility for Biopharmaceuticals, Guru Nanak Khalsa College, Mumbai, India
Geetika Preman

Department of Five-Year Integrated Course in Bioanalytical Sciences, Guru Nanak Khalsa College, Mumbai, India
Kunal Gharat

Department of Five-Year Integrated Course in Bioanalytical Sciences, Guru Nanak Khalsa College, Mumbai, India
Muskaan Mulani

Department of Five-Year Integrated Course in Bioanalytical Sciences, Guru Nanak Khalsa College, Mumbai, India
Shalmali Pendse

National Facility for Biopharmaceuticals, Guru Nanak Khalsa College, Mumbai, India
Kabir Thakur

National Facility for Biopharmaceuticals, Guru Nanak Khalsa College, Mumbai, India
Anjali Bhosale

National Facility for Biopharmaceuticals, Guru Nanak Khalsa College, Mumbai, India
Siddhartha Pandya

Department of Five-Year Integrated Course in Bioanalytical Sciences, Guru Nanak Khalsa College, Mumbai, India
Arpita Marick

National Facility for Biopharmaceuticals, Guru Nanak Khalsa College, Mumbai, India

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Vikas Jha, Ajit Kumar, Geetika Preman, Kunal Gharat, Muskaan Mulani, et al. (2022). Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach. Biomedical Statistics and Informatics, 7(2), 31-40. https://doi.org/10.11648/j.bsi.20220702.13

Copy | Download

ACS Style

Vikas Jha; Ajit Kumar; Geetika Preman; Kunal Gharat; Muskaan Mulani, et al. Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach. Biomed. Stat. Inform. 2022, 7(2), 31-40. doi: 10.11648/j.bsi.20220702.13

Copy | Download

AMA Style

Vikas Jha, Ajit Kumar, Geetika Preman, Kunal Gharat, Muskaan Mulani, et al. Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach. Biomed Stat Inform. 2022;7(2):31-40. doi: 10.11648/j.bsi.20220702.13

Copy | Download

@article{10.11648/j.bsi.20220702.13,
  author = {Vikas Jha and Ajit Kumar and Geetika Preman and Kunal Gharat and Muskaan Mulani and Shalmali Pendse and Kabir Thakur and Anjali Bhosale and Siddhartha Pandya and Arpita Marick},
  title = {Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach},
  journal = {Biomedical Statistics and Informatics},
  volume = {7},
  number = {2},
  pages = {31-40},
  doi = {10.11648/j.bsi.20220702.13},
  url = {https://doi.org/10.11648/j.bsi.20220702.13},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.bsi.20220702.13},
  abstract = {While tuberculosis is a curable disease, Mycobacterium tuberculosis (M. tb), its etiological agent, remains a major human pathogen. For thousands of years of human life, this pathogen leads to more human deaths than any other infectious agent. Relatively affordable new drugs for the treatment of this lethal disease need to be developed in light of global TB infections. The current study aims to screen a broad spectrum of bioactive compounds, along with standard anti-tubercular drugs against Topoisomerase II protein of Mtb. The Lipinski rule was employed for the initial screening of the phytochemicals based on their pharmacokinetic properties. The 75 shortlisted compounds were subjected to molecular docking analysis with the Topoisomerase II receptor, which revealed six molecules Glyceollin-I, Fumarine, Chelidonine, Alstonine, Tuberosin, and Asarinin, as potential inhibitors against the receptor. Furthermore, the toxicity profiles of these six compounds were evaluated, and Glyceollin-I, Alstonine, and Tuberosin were shown to be the safest as compared to the others. The MD simulation analyses of these compounds in complexation with the receptor confirmed that the receptor-Alstonine complex was the most stable. Thus, the findings of our study will contribute to a better understanding of the Mycobacterial Topoisomerase II protein target and pave the way for the development of a novel therapeutic candidate drug to treat this disease.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - Investigation of the Anti-tubercular Potential of Selected Phytochemicals Using Computational Approach
AU  - Vikas Jha
AU  - Ajit Kumar
AU  - Geetika Preman
AU  - Kunal Gharat
AU  - Muskaan Mulani
AU  - Shalmali Pendse
AU  - Kabir Thakur
AU  - Anjali Bhosale
AU  - Siddhartha Pandya
AU  - Arpita Marick
Y1  - 2022/06/30
PY  - 2022
N1  - https://doi.org/10.11648/j.bsi.20220702.13
DO  - 10.11648/j.bsi.20220702.13
T2  - Biomedical Statistics and Informatics
JF  - Biomedical Statistics and Informatics
JO  - Biomedical Statistics and Informatics
SP  - 31
EP  - 40
PB  - Science Publishing Group
SN  - 2578-8728
UR  - https://doi.org/10.11648/j.bsi.20220702.13
AB  - While tuberculosis is a curable disease, Mycobacterium tuberculosis (M. tb), its etiological agent, remains a major human pathogen. For thousands of years of human life, this pathogen leads to more human deaths than any other infectious agent. Relatively affordable new drugs for the treatment of this lethal disease need to be developed in light of global TB infections. The current study aims to screen a broad spectrum of bioactive compounds, along with standard anti-tubercular drugs against Topoisomerase II protein of Mtb. The Lipinski rule was employed for the initial screening of the phytochemicals based on their pharmacokinetic properties. The 75 shortlisted compounds were subjected to molecular docking analysis with the Topoisomerase II receptor, which revealed six molecules Glyceollin-I, Fumarine, Chelidonine, Alstonine, Tuberosin, and Asarinin, as potential inhibitors against the receptor. Furthermore, the toxicity profiles of these six compounds were evaluated, and Glyceollin-I, Alstonine, and Tuberosin were shown to be the safest as compared to the others. The MD simulation analyses of these compounds in complexation with the receptor confirmed that the receptor-Alstonine complex was the most stable. Thus, the findings of our study will contribute to a better understanding of the Mycobacterial Topoisomerase II protein target and pave the way for the development of a novel therapeutic candidate drug to treat this disease.
VL  - 7
IS  - 2
ER  -

Copy | Download